Kineret (anakinra) / SOBI - LARVOL DELTA

Utility of anakinra in Crimean Congo haemorrhagic fever with haemophagocyctic lymphohistiocytosis: a case report. (PubMed, Trans R Soc Trop Med Hyg) - "After 14 d of anakinra, she was discharged in full recovery. Anakinra may be a new therapeutic agent in CCHF, in which inflammation plays important role."

Journal • Anorexia • Fatigue • Immunology • Infectious Disease • Inflammation • Pediatrics • Rare Diseases

Haemophagocytic histiolymphocytis after solid organ transplantation: preliminary data from a cohort study (ERA 2025) - "Other immunomodulators included tocilizumab (25%), etoposide (10%), the apolipoprotein A1 biomimetic CER-001 (<10%) anakinra (< 5%), rituximab (<5%), and plasma exchange (<5%). Our study highlights the heterogeneity of clinico-biological profiles and therapeutic approaches for adult SOT-HLH. A high incidence of HLH was observed during the early months post-SOT, primarily driven by severe viral or bacterial infections, and associated with a high mortality rate. Future studies investigating optimal strategies for managing HLH in SOT patients remain an urgent medical need."

Immunology • Infectious Disease • Oncology • Solid Organ Transplantation • Transplantation • APOA1

Four months of treatment with anakinra combined with glucocorticoids for giant cell arteritis: a multicenter, randomized, double-blind, placebo-controlled trial. (PubMed, Arthritis Res Ther) - P3 | "Although prematurely discontinued, this study does not support the use of 4 months of treatment with anakinra combined with GCs to reduce the risk of relapse or GC exposure."

Clinical • Journal • Giant Cell Arteritis • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Minocycline in chronic management of febrile infection-related epilepsy syndrome (FIRES): a case series and literature review of treatment strategies. (PubMed, Acta Epileptol) - P=N/A | "Additionally, a short literature review was conducted to explore various management strategies for chronic FIRES, including IL-1 receptor antagonist (anakinra) and IL-6 receptor antagonist (tocilizumab), centro-median thalamic nuclei deep brain stimulation, cannabidiol, responsive neurostimulation, intrathecal dexamethasone, ketogenic diet, and vagus nerve stimulation. In conclusion, considering the existing research on the etiological mechanisms of FIRES and based on our preliminary findings on the anti-inflammatory and antiepileptic properties of minocycline, early initiation of minocycline therapy in the chronic phase of FIRES should be explored further.Trial registrationClinicaltrials.gov (NCT05958069, retrospectively registered 22 July 2023)."

Journal • Review • CNS Disorders • Epilepsy • Infectious Disease • IL6

A Phase I/II, Open-Label, Multicenter Clinical Study to Evaluate Safety, Tolerability, and Reduction of Chemotherapy-Related Cardiotoxicity of Anakinra in Pediatric Acute Myeloid Leukemia Patient (ChiCTR) - P1/2 | N=368 | Not yet recruiting | Sponsor: Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center, Shanghai Jiao Tong Universit

New P1/2 trial • Acute Myelogenous Leukemia • Cardiovascular • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6-mediated gene editing in hematopoietic stem cells. (PubMed, Cell Rep Med) - "Importantly, we identify treatment with Anakinra, an IL-1 signaling antagonist, as a promising strategy to enhance polyclonal output in HDR-edited cells while minimizing genotoxicity risks associated with the editing procedure. Overall, our findings present strategies to overcome key hurdles in HDR-based HSPC gene therapies, providing a framework for enhancing their efficacy and safety in clinical applications."

Journal • Gene Therapies • Genetic Disorders • Inflammation • Transplantation

Outpatient administration of CAR T-cell therapy: A University of Arizona Cancer Center experience. (ASCO 2025) - "Methods to implement this in an outpatient setting have included early CRS (cytokine release syndrome) intervention with tocilizumab and multidisciplinary support including patient access to healthcare providers 24 hours a day (2-4)...CAR T-cell products administered included axicabtagene ciloleucel (n = 2, 5.1%), tisagenlecleucel (n = 28, 71.8%), and ciltacabtagene autoleucel (n = 9, 23.1%)...Among these, 62% (8) were treated with steroids, and 23% (3) received Anakinra... Our study shows CAR T-cell therapy can be safely administered in the outpatient setting with close monitoring, reducing inpatient LOS significantly."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hypotension • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Plasma Cell Leukemia

Outpatient administration of idecabtagene vicleucel in relapsed refractory multiple myeloma without planned prophylaxis or remote monitoring. (ASCO 2025) - "Fludarabine plus cyclophosphamide was the lymphodepletion regimen used for all patients...Most CRS events occurred within 1 day of infusion (83%) and Tocilizumab was used to manage all CRS events. Grade 1 ICANS was reported in one patient for whom steroids and Anakinra was used for management... Our findings indicate that outpatient administration of Idecabtagene Vicleucel is feasible with adequate institutional experience and proper toxicity monitoring and management. The majority of patients were still living, so longer follow up time is required to explore the full outpatient experience for patients on this treatment and to understand all pertinent patient outcomes."

Clinical • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Oncology

Real-world outcomes of CAR-T in the outpatient setting. (ASCO 2025) - "The most commonly used products were axicabtagene ciloleucel (43.0%), idecabtagene vicleucel (15%), and brexucabtagene autoleucel (11.2%). Any-grade Cytokine release syndrome (CRS) was reported in 66.4% of patients for which Tocilizumab was administered in 92.7%. Any-grade neurotoxicity was reported in 27.7% of which steroids with/without Anakinra was administered in 95.8%... Our experience revealed that treatment with CAR-T in the outpatient setting is safe and feasible with adequate institutional experience. Proper toxicity monitoring and management could help optimize healthcare utilization, and CAR-T accessibility."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed/refractory (R/R) secondary central nervous system lymphoma (SCNSL). (ASCO 2025) - "Funded by U.S. National Institutes of Health, Kite, a Gilead Company Background: Axi-cel is an autologous anti-CD19 CAR T-cell therapy that demonstrated durable, long-term efficacy and manageable safety in R/R LBCL...Of 56 pts with CRS and/or ICANS, tocilizumab, corticosteroids, and anakinra were used in 68%, 73%, and 7% of pts, respectively... With 4-y median follow-up, this real-world study highlights the potential use of axi-cel as an option to treat this challenging group of pts. Further studies are needed to improve response durability."

Clinical • Real-world • Real-world evidence • CNS Disorders • CNS Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Oncology • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Thrombocytopenia

A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma. (ASCO 2025) - P1 | "Effective treatments in the recurrent setting following upfront chemoradiation and adjuvant temozolomide are limited...Toxicity otherwise has been primarily related to tumor inflammation-associated neurotoxicity (TIAN), observed after 29 of 36 infusions (81%), and managed acutely with anakinra and dexamethasone... Intracranial administration of B7H3-CART in recurrent GBM is technically feasible and safe. TIAN was common but manageable and reversible with immunomodulators. Correlative analyses on surgical tissue, CSF, and serum are ongoing."

CAR T-Cell Therapy • P1 data • Brain Cancer • CNS Tumor • Glioblastoma • Hypertension • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • CD276

Safety and tolerability of intraventricular CARv3-TEAM-E T cells following lymphodepleting chemotherapy in recurrent glioblastoma: INCIPIENT trial. (ASCO 2025) - P1 | " In a phase 1, first-in-human study (INCIPIENT, NCT05660369), patients with recurrent GBM with EGFRvIII mutation and/or EGFR amplification were eligible to receive up to 6 intraventricular doses of 10x106 CAR T cells via Ommaya catheter after lymphodepleting chemotherapy (LDC) with fludarabine and cyclophosphamide. Intraventricular CARv3-TEAM-E infusions were well tolerated, even with multiple doses, and no DLTs were noted. Toxicity was manageable in all patients with supportive care and anakinra was administered to 3 patients. Steroids were not required to manage toxicity."

Clinical • Brain Cancer • CNS Tumor • Febrile Neutropenia • Glioblastoma • Neutropenia • Oncology • Solid Tumor • EGFR

Predictors and clinical outcomes of CMV reactivation in CAR-T therapy: A systematic review. (ASCO 2025) - "Most patients received axicabtagene ciloleucel (71%) and had lymphoma (88%)...Immunosuppressive therapy use, including steroids (56% vs. 42.8%) and combination therapy with tocilizumab and anakinra (12% vs. 5%), was significantly higher in the R group... CMV reactivation is a significant complication in CAR-T therapy, linked to worse outcomes, including increased mortality, relapse, and NRM. Predictors include BCMA-targeted CAR-T therapy, prior allogeneic HSCT, severe CRS/ICANS, and associated treatments. Targeted CMV monitoring, prophylaxis, and immunosuppressive strategies are essential for mitigating reactivation risks and improving outcomes in CAR-T recipients."

Clinical • Clinical data • Review • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Malignancies • Lymphoma • Oncology

Diurnal rhythms in chimeric antigen receptor T cell performance: an observational study of 670 patients. (PubMed, medRxiv) - "Simultaneously, for every hour CAR-T cell infusion was delayed, the adjusted odds of severe ICANS rose by 17% (aOR 1·17, 95% CI 1·01-1·34, p=0·031), and anakinra prescription rose by 26% (aOR 1·26, 95% CI 1·07-1·49, p=0·006)...The findings also have implications for clinical trials applying CAR-T cells to new indications. Without controlling for time-of-treatment, diurnal rhythms in CAR-T cell effectiveness could be a significant confounder that could lead to false-negative or false-positive conclusions."

Journal • Observational data • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Oncology • Respiratory Diseases • Transplantation

TREATMENT PATTERNS AND DETERMINANTS OF DMARD SWITCHING IN EUROPEAN RHEUMATOID ARTHRITIS COHORTS: A MULTI-NATIONAL ANALYSIS (EULAR 2025) - "The type of DMARD initiated was categorised as MTX, other conventional synthetic DMARD (csDMARD: hydroxychloroquine, sulfasalazine, leflunomide, cyclosporine, azathioprine), tumor necrosis factor inhibitors (TNFi: adalimumab, infliximab, etanercept, certolizumab pegol, golimumab), non-TNFi (abatacept, anakinra, rituximab, tocilizumab, sarilumab), and Janus Kinase inhibitors (JAKi: tofacitinib, baricitinib, upadacitib, filgotinib). Despite similar treatment guidelines within the Europe countries, there are clear differences in the use and sequencing of DMARDs in newly diagnosed RA, particularly for second-line DMARDs. Further analyses are needed to understand how these differences affect remission rates and other treatment outcomes in RA."

Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

EFFICACY OF A BD2-SELECTIVE BET INHIBITOR IN ANIMAL MODELS OF RHEUMATOID ARTHRITIS BY INHIBITION OF NF-KB DRIVEN INFLAMMATORY PATHWAYS (EULAR 2025) - "Antagonists to these cytokines (e.g. adalimumab, anakinra, tocilizumab) are known to be effective in the treatment of RA...Objectives: To evaluate the efficacy of orally administered VYN202 in collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) models in rats compared to vehicle and reference compounds, dexamethasone (glucocorticoid), GSK620 (a less potent, earlier generation BD2-selective BET inhibitor), and upadacitinib (a Janus kinase inhibitor approved in RA)... BD2-selective BET inhibition with VYN202 represents a novel approach to treatment of NF-κB–mediated diseases such as RA. A phase 1b study of VYN202 in RA is planned."

Preclinical • Cardiovascular • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IL17A • IL23A • IL6

LOW INCIDENCE OF NEONATAL INFECTION WITH TNF AND NON-TNF BIOLOGIC DMARD USE IN THE SECOND AND THIRD TRIMESTERS OF PREGNANCY (EULAR 2025) - "Patients were treated with the following biologics in pregnancy: 27 were on certolizumab, 17 were on adalimumab, 13 were on etanercept (including one in combination with risankizumab), 9 were on infliximab, 3 were on secukinumab, 3 were on golimumab, 2 were on rituximab and 1 was on anakinra. In this single center study, the late exposure to biologics in pregnancy yielded a very low incidence of infection in newborns to mothers with autoimmune conditions. The results of this study support the most recent 2024 EULAR Update in taking a more permissive approach to the continuation of biologics in pregnancy for the treatment of autoimmune diseases."

Ankylosing Spondylitis • Crohn's disease • Dermatology • Gastroenterology • Hematological Disorders • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Obstetrics • Pneumonia • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Respiratory Syncytial Virus Infections • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

INDICATIONS, EFFICACY, AND SAFETY OF CANAKINUMAB: REAL LIFE EXPERIENCE OF A TERTIARY RHEUMATOLOGY CLINIC (EULAR 2025) - "CAN was initiated primarily due to inadequate responses to Anakinra (42.8%) and adverse reactions to Anakinra (40.5%) in MEFV-positive FMF patients (Table 2). This highlights the clinical utility of CAN in managing refractory FMF and other autoinflammatory conditions. CAN demonstrates robust efficacy and safety, with flexible dosing strategies offering additional benefits. These findings support CAN’s role as a cornerstone therapy in autoinflammatory diseease field of rheumatology practice."

Clinical • Genetic Disorders • Hematological Disorders • Immunology • Inflammation • Rheumatology • IL1B

EVALUATION OF MEDICATION ADHERENCE OF FMF PATIENTS TRANSITIONED FROM A PEDIATRIC CLINIC TO AN ADULT CLINIC: A CROSS-SECTIONAL STUDY (EULAR 2025) - "It included 256 patients who were transferred from the pediatric rheumatology clinic between 2017 and 2024 and who were being treated with medications such as colchicine, anakinra, or canakinumab. In FMF, being diagnosed at a younger age and longer disease duration negatively effects medication compliance. Being diagnosed at a younger age may have negative effects in terms of understanding the disease, difficulty in using medication, and adequate parental support. More studies are needed on this subject."

Adherence • Clinical • Observational data • Amyloidosis • Genetic Disorders • Pediatrics • Rheumatology

INSIGHTS FROM A ONE-YEAR INTERNATIONAL MONTHLY QUIZ ON AA AMYLOIDOSIS CAUSES: ENGAGING 2,597 VOTERS ACROSS FRENCH-SPEAKING COUNTRIES (EULAR 2025) - "Topics covered were, in order of frequency, 10 rare causes of AA amyloidosis (including variable common immune deficiency, hidradenitis suppurativa, inflammatory lymphomas, xanthogranulomatous pyelonephritis, sickle cell disease, PSTPiP1 mutations, anakinra, checkpoint inhibitors such as atezolizumab, Behçet’s disease and hereditary epidermolysis bullosa), 6 on the epidemiology of AA amyloidosis in some countries (such as Brazil, Portugal, Algeria and Turkey), familial Mediterranean fever, anti-inflammatory cytokine biotherapies and disease progression or kidney transplantation; Only one involved inflammatory rheumatism (gout), a classic but declining aetiology of AA amyloidosis. The “AA challenge” educational project brought together >10 French-speaking countries to discuss the various causes of AA amyloidosis. This project attracted more than 2500 colleagues from at least 8 different specialties. The high number of responses to the questionnaire indicates an..."

Amyloidosis • Cardiovascular • Crohn's disease • Dermatology • Gastroenterology • Genetic Disorders • Gout • Hematological Disorders • Hematological Malignancies • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Lymphoma • Nephrology • Obesity • Oncology • Pediatrics • Rare Diseases • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Sickle Cell Disease • Spondylarthritis • Tuberculosis • PSTPIP1

Validation of sJADAS in adult patients with Still's disease (EULAR 2025) - "Anakinra was the most frequently used biological therapy (n=30 visits), followed by tocilizumab (n=14 visits) and canakinumab (n=9 visits). Methotrexate was used in 21 visits whereas glucocorticoids (GCs) in 45 visits... sJADAS may be a valuable tool for the assessment of disease activity in adult patients with Still’s disease and may be used to guide therapeutic decisions. Larger studies are needed to validate its use in clinical practice. Sensitivity and specificity across disease activity statuses ID, Inactive Disease; MDA, Minimal Disease Activity; MoDA, Moderate Disease Activity; HDA, High Disease Activity; PPV, Positive Predictive Value; NPV, Negative predictive Value"

Clinical • Idiopathic Arthritis • Immunology • Pediatrics • Rheumatology

Factors associated with efficacy and safety of Anakinra for the treatment of acute crystals related arthritis. (EULAR 2025) - "Background: Anakinra is recommended after failure of colchicine, corticosteroids and non-steroid anti-inflammatory drugs (NSAID) in the treatment of gout and calcium pyrophosphate deposition (CPPD) flares...In the univariate analysis, patient who showed less efficacy of anakinra had more CPPD (38.1% vs 17.3%), a longer CRD duration (3 years [0-10] vs 0.5 [0-3]), more diabetes (52% vs 29%), a higher baseline CRP (112mg/L [71-230] vs 83 [30-153]), and received more frequently NSAIDs (14% vs 4.9%) and febuxostat (35% vs 14%)... In our retrospective study, efficacy of anakinra was observed in more than 90% of patients experiencing a CRD- flare. Diabetes and longer duration of CRD were associated with a lack of efficacy of anakinra. Female sex and higher CRP level were associated with an increased risk of infection during the month following treatment."

Clinical • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Coronary Artery Disease • Depression • Diabetes • Diabetic Nephropathy • Gout • Heart Failure • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pneumonia • Psychiatry • Renal Disease • Rheumatoid Arthritis • Rheumatology • Solid Organ Transplantation

IL-1 inhibition in patients with VEXAS syndrome – a retrospective international multicenter study (EULAR 2025) - "Demographic and clinical data, including genetic data, medication use and dose (prednisone, immunosuppressive, biologics and targeted synthetic medications), response to treatment and adverse events were collected anonymously from medical files. Eventhough VEXAS was first described more than 4 years ago, the best treatment approach remains unknown. Drug survival of canakinumab was higher than that of anakinra – with survival in patients receiving the 300 mg/month dose of more than 3 years on average, while in the 150 mg/month dose and anakinra group – survival was ~6 months. This is probably due to a lower adverse event rate and a higher rate of response in the canakinumab group."

Retrospective data • Anemia • Dermatology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Myelodysplastic Syndrome • Neutropenia • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • CRP

The CARDIOSTILL Study: A French Observational Retrospective Study on Cardiac Involvement in Adult Still's Disease. (EULAR 2025) - "Less than 50% of patients treated with glucocorticoids (GC) alone achieved complete remission, whereas 90-100% of those who combined GC with anakinra or tocilizumab achieved remission. This study represents the largest reported series of AOSD patients with cardiac involvement. The fact that nearly 10% of patients were asymptomatic (raises the question of systematic screening, particularly in cases of highly active AOSD. Our findings support the early use of IL-1 or IL-6 inhibitors in combination with GC, along with multidisciplinary management."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Hepatology • Immunology • Inflammation • Musculoskeletal Pain • Pain • Pulmonary Disease • Respiratory Diseases • CRP

A window of opportunity in Still's disease: the early introduction of IL-1 inhibitors for achieving clinical inactive disease (EULAR 2025) - "Objectives: The objective of this study is to observe if patients with SD early treated with IL-1i achieve higher rates of clinical inactive disease (CID), compared to those late treated during the disease course, with either anakinra or canakinumab. Patients treated with IL-1i within 6M from onset had higher CID rates than those late-treated. Despite the significance was not achieved, our data are in line with those reported in other sJIA cohorts of IL-1i treated (3,4), which showed that early treatment (ranging between <3 and <12 M) was associated with higher CID remission rates than late treatment. Regarding safety, we did not observe SAEs related to IL-1i therapy and flares occurred mostly after IL-1i discontinuation."

Clinical • Idiopathic Arthritis • Immunology • Rheumatology